	CH_2

REMARKS

Claims 1 to 41 and 43 to 95 are pending in the application. Claims 1, 2, 8, 9, 10, 16, 35, 50, 52, 53, 55, 65, 68, 73, and 91 have been amended, and new claims 96 to 100 have been added, herein. No claims have been cancelled. Because the amendments remove issues for appeal, Applicants respectfully request entry thereof. MPEP § 714.13.

Preliminarily, Applicants note the following with respect to the claim amendments. Claims 1 and 2 have been amended to correct an inadvertent drafting error by replacing the phrase "ring J contain" with the phrase "one of A, B, C, D, E, or F contains." Those skilled in the art would readily understand that, for the proviso "ring J contain at least one carbon atom that is saturated" to have any relevant meaning, the proviso must relate to the moieties A-F, rather than ring J, since ring J, as it is currently defined, already contains a saturated carbon (the carbon between A and F). Support for the amendments is found in the specification as filed, at, for example, Tables VII and VIII, which depict compounds that all contain at least one saturated carbon atom in the A-F moieties.

Claims 1 and 2 have further been amended to correct an inadvertent typographical error by adding the word "does" after "ring J" in the phase "ring J not contain two adjacent ring O atoms."

Claims 1 and 2 have been amended to correct an inadvertent drafting error by deleting the fourth proviso relating to ring J. Specifically, claims 1 and 2 have been amended to delete the proviso stating that "when G is a bond, ring J can be heteroaryl." Those skilled in the art would readily understand, based on the structural formula of ring J, that the ring cannot be

construed to be a heteroaryl group due to the presence of the unsaturated carbon atom between A and F. To retain the subject matter of the deleted proviso, new claims 96 and 97 have been added. Support for claims 96 and 97 is found in the specification as filed, at, for example, the deleted proviso (page 8, line 22, and claim 1, page 91, line 27), compounds (33) and (34) in Figure 7, and compounds (73) and (74) in Figure 17.

Claim 8 has been amended to add the phrase "or NR^{7A}" to the end of the claim. Support for the amendment is found in the specification as filed, at, for example, page 12, lines 9 to 10. Claim 9 has been amended to replace the phrase "preferably wherein R^{13} is H or R^{7A}" with the phrase "Q is NR^{7A}," support for which is found in the specification as filed, at, for example, page 12, lines 9 to 10. In addition, claim 10 has been amended to depend from claim 8, rather than from claim 9.

Claim 16 has been amended to delete the phrase "3-, 4-, 5-, or 6-membered." Support for the amendment is found in the specification as filed, at, for example, page 7, line 13 to page 8, line 8.

Claim 35 has been amended to exclude compound II-49 and to recite the constituent variables of the compounds encompassed by the claims. New independent claim 98 has been added, which is directed to the genus represented by compound (57) in Figure 12. New claim 99, which depends from claim 98, is directed to compound II-49, deleted from claim 35. Support for the amendments is found in the specification as filed, at, for example, original claim 35 and Figure 12.

Claim 50 has been amended to correct an inadvertent typographical error by replacing the phrase "-O-(C=O)-CH_3" with the phrase "-O-C(=O)-CH_3."

Claim 52 has been amended to replace the phrase "W is CHR^{17}" with the phrase "W is $CR^{18}R^7$." Support for the amendment is found in the specification as filed, at, for example, page 11, lines 17-18. Claim 53 has been amended to replace "R^{17}" with "R^7." Support for the amendment is found in the specification as filed, at, for example, page 7, line 13 to page 8, line 8. Claim 53 has also been amended to correct an inadvertent typographical error by deleting the second occurrence of the word "wherein."

Claim 55 has been amended to correct an inadvertent typographical error by deleting the phrase "R^{7A} is".

Claim 65 has been amended to correct an inadvertent typographical error by amending the claim to depend from claim 64 rather than from claim 23.

Claim 68 has been amended to correct an inadvertent typographical error by deleting the second occurrence of the word "comprising."

Claim 91 has been amended by adding the following phrase to the end of the claim: ", the method comprising providing a compound of claim 1 in an amount sufficient to result in the receptor being contacted with an effective inhibitory amount of the compound." Support for the amendment is found in the specification as filed, at, for example, page 16, lines 14 to 20.

New claim 100 has been added, which is directed to the compounds of Table 9. Support for the amendment is found in the specification as filed, at, for example, Table 9.

Applicants respectfully request reconsideration of the rejections of record in view of the foregoing amendments and the following remarks.

Alleged Lack of Enablement

Claim 73 has been rejected under 35 U.S.C. § 112, first paragraph for alleged lack of enablement. The Office Action asserts that the specification fails to enable the prevention of prostate disorders. (Office Action dated December 19, 2002, pages 2 to 3). Without conceding the correctness of this assertion, to advance prosecution by further clarifying the claimed subject matter, claim 73 has been amended to delete the phrase "or prevention." Support for the amendment is found in the specification as filed, at, for example, page 15, lines 6 to 11. The rejection has been obviated, and Applicants respectfully request withdrawal thereof.

Alleged Indefiniteness

Claim 73 has been rejected under 35 U.S.C. § 112, second paragraph as indefinite because the preamble of the claim recites "treating prostate disorders," while the remainder of

the claim is allegedly directed to "such treatment or prevention." As discussed above, claim 73 has been amended to delete the phrase "or prevention," obviating the rejection. Accordingly, Applicants respectfully request withdrawal thereof.

Claim Objections

Claims 1 to 58, 60, 61, 63 to 65, 73, 74, and 95 have been objected to for containing non-elected subject matter. The Office Action suggests limiting the claims to the generic concept set forth by the Examiner in the Office Action issued May 7, 2002. Applicants respectfully traverse the objection because it is Applicants' understanding that the election of species requirement was levied to aid the Examiner in an initial search and examination of the claimed subject matter. It is Applicants' further understanding that if the elected species were found to be allowable over the prior art, the search and examination would be expanded to include additional species, until the search and examination covered the full scope of the generic claim. Accordingly, it is Applicant's understanding that, since the art-based rejections have been overcome, the search and examination of the claimed subject matter should be expanded, and Applicants are not required to cancel "non-elected" subject matter.

In the Office Action issued February 8, 2002, Applicants were required under 35 U.S.C. § 121 to elect a single disclosed species. In a response to Office Action, filed March 8, 2002, Applicants elected the species of Formula II in claim 21 wherein Q is NR^{13} or R^{7A} and W is $CR^{18}R^{7}$. Applicants stated that a specific compound falling within this election is compound II-4 in Table 7 on page 48 of the specification. (See page 2). Applicants further stated that they assumed that the election was for searching purposes only, and that should the elected species be found to be free of the prior art, the full scope of the claims would be Examined. *Id.*

In the next Office Action, issued May 7, 2002, the Office Action identified a generic concept, along with the elected embodiment, for examination. (See page 2). The Office Action also stated that composition claims 63, 64, and 65 and method claims 73 and 75 were identified for examination, and all other composition and method claims were restricted out

for being drawn to different subject matter. *Id.* The Office Action further stated the following:

> [t]he withdrawn subject matter of claims 1-58, 60, 61, 63, 64, 65, 73, and 74 (in part) and claims 59, 62, 66-72, and 75-94 in their entirety is properly restricted as said subject matter differs in structure and element from the elected subject matter so as to be patentably distinct therefrom. i.e. a reference which anticipated the elected subject matter would not even render obvious the withdrawn subject matter and fields of search are not co-extensive.

Id. at pages 2 to 3.

In a Response to the Office Action, filed September 20, 2002, Applicants stated that a telephonic interview had been held on September 5, 2002 between Applicants' attorney and Dr. Eric Voelk, and Examiners Wright and Chang in which the election of species requirement had been discussed. The Response states that Applicants' attorney and Dr. Eric Voelk were informed that the search conducted pursuant to the species election included embodiments wherein ring "J" is a three to seven membered ring containing oxygen and substitutents according to the claims. The Response further states that Applicants' attorney and Dr. Eric Voelk were also informed that, in the event that the present art-based rejections were overcome, the search would be expanded to include certain other ring "J" embodiments, such as to be agreed upon at a later date.

Accordingly, it is Applicants' understanding that, since the art-based rejections have been overcome, the search and examination of the claimed subject matter should now be expanded. Applicants respectfully ask the Examiner to withdrawn the objection, and to search and examine the full scope of the generic claims.

Conclusion

In view of the foregoing, Applicants submit that the claims are in condition for allowance, and an early Office Action to that effect is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**"

Respectfully submitted,

Date: **March 18, 2003**

Jane E. Inglese, Ph.D.
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place B 46th Floor
Philadelphia, PA 19103
(215)568-3100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

The claims have been amended as follows.

1. (Twice Amended) A compound having the Formula I:



I

wherein:

ring B and ring F, independently, and each together with the carbon atoms to which they are attached, are selected from the group consisting of:

a) an unsaturated 6-membered carbocyclic aromatic ring in which from 1 to 3 carbon atoms may be replaced by nitrogen atoms;

b) an unsaturated 5-membered carbocyclic aromatic ring; in which, optionally, either

1) one carbon atom is replaced with an oxygen, nitrogen, or sulfur atom;

2) two carbon atoms are replaced with a sulfur and a nitrogen atom, an oxygen and a nitrogen atom, or two nitrogen atoms; or

3) three carbon atoms are replaced with three nitrogen atoms;

R^7 is



wherein:

m is 0-4;

G is a bond; or alkylene having 1 to 4 carbons, wherein the alkylene group is unsubstituted, or substituted with $NR^{11A}R^{12A}$ or OR^{19};

R^{11A} and R^{12A} are the same as R^{11} and R^{12};

R^{19} is selected from the group consisting of H, alkyl, acyl, and $C(=O)NR^{11A}R^{12A}$;

R^8 is selected from the group consisting of $O(C=O)NR^{11}R^{12}$, -CN, acyloxy, alkenyl, $-O-CH_2-O-(CH_2)_2-O-CH_3$, halogen and R^{1A} wherein R^{1A} is the same as R^1;

A and B are independently selected from the group consisting of O, N, S, CHR^{17}, $C(OH)R^{17}$, C(=O), and CH_2=C; or A and B together can form -CH=CH-;

C and D are independently selected from the group consisting of a bond, O, N, S, CHR^{17}, $C(OH)R^{17}$, C(=O) and CH_2=C;

E and F are independently selected from the group consisting of a bond, O, N, S, C(=O), and $CH(R^{17})$;

R^{17} is selected from the group consisting of H, substituted or unsubstituted alkyl, alkoxycarbonyl, and substituted or unsubstituted alkoxy;

wherein:

1) ring J contains 0 to 3 ring heteroatoms;

2) any two adjacent hydroxyl groups of ring J can be joined in a dioxolane ring;

3) any two adjacent ring carbon atoms of ring J can be joined to form a fused aryl or heteroaryl ring;

4) any two adjacent ring nitrogen atoms of ring J can be joined to form a fused heterocyclic ring which can be substituted with 1 to 3 alkyl or aryl groups;

provided that:

1) [ring J contain] one of A, B, C, D, E, or F contains at least one carbon atom that is saturated;

2) ring J does not contain two adjacent ring O atoms;

3) ring J contains a maximum of two ring C(=O) groups;

[4) when G is a bond, ring J can be heteroaryl;]

Q is selected from the group consisting of O, S, NR^{13}, NR^{7A} wherein R^{7A} is the same as R^7, CHR^{15}, $X^3CH(R^{15})$, and $CH(R^{15})X^3$, wherein X^3 is selected from the group consisting of -O-, -S-, $-CH_2-$, NR^{7A}, and NR^{13};

W is selected from the group consisting of $CR^{18}R^7$ and CHR^{50} where R^{50} is alkyl having from 1 to 4 carbons, -OH, alkoxy having from 1 to 4 carbons, $-OC(=O)R^9$, $-OC(=O)NR^{11}R^{12}$, $-O(CH_2)_pNR^{11}R^{12}$, $-O(CH_2)_pOR^{10}$, substituted or unsubstituted arylalkyl having from 6 to 10 carbons, and substituted or unsubstituted heteroarylalkyl;

R^{13} is selected from the group consisting of H, $-SO_2R^9$, $-CO_2R^9$, $-C(=O)R^9$, $-C(=O)NR^{11}R^{12}$, alkyl of 1-8 carbons, alkenyl having 2-8 carbons, and alkynyl having 2-8 carbons; and either

1) the alkyl, alkenyl, or alkynyl group is unsubstituted; or

2) the alkyl, alkenyl, or alkynyl group independently is substituted with 1 to 3 groups selected from the group consisting of aryl having from 6 to 10 carbons, heteroaryl, arylalkoxy, heterocycloalkoxy, hydroxylalkoxy, alkyloxy-alkoxy, hydroxyalkylthio, alkoxy-alkylthio, F, Cl, Br, I, -CN, $-NO_2$, -OH, $-OR^9$, - $X^2(CH_2)_pNR^{11}R^{12}$, $-X^2(CH_2)_pC(=O)NR^{11}R^{12}$, $-X^2(CH_2)_pOC(=O)NR^{11}R^{12}$, $-X^2(CH_2)_pCO_2R^9$, $X^2(CH_2)_pS(O)_yR^9$,

$-X^2(CH_2)_pNR^{10}C(=O)NR^{11}R^{12}$, $-OC(=O)R^9$, $-OCONHR^2$, -O-tetrahydropyranyl, $-NR^{11}R^{12}$, $-NR^{10}CO_2R^9$, $-NR^{10}C(=O)NR^{11}R^{12}$, $-NHC(=NH)NH_2$, $NR^{10}C(=O)R^9$, $-NR^{10}S(O)_2R^9$, $-S(O)_yR^9$, $-CO_2R^2$, $-C(=O)NR^{11}R^{12}$, $-C(=O)R^2$, $-CH_2OR^{10}$, $-CH=NNR^2R^{2A}$, $-CH=NOR^2$, $-CH=NR^9$, $-CH=NNHCH(N=NH)NH_2$, $-S(=O)_2NR^2R^{2A}$, $-P(=O)(OR^{10})_2$, $-OR^{14}$, and a monosaccharide having from 5 to 7 carbons wherein each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H, alkyl having from 1 to 4 carbons, alkylcarbonyloxy having from 2 to 5 carbons, or alkoxy having from of 1 to 4 carbons;

R^{15} is selected from the group consisting of H, OR^{10}, SR^{10}, R^{7A}, and R^{16};

R^{16} is selected from the group consisting of alkyl of 1 to 4 carbons; phenyl; naphthyl; arylalkyl having 7 to 15 carbons, $-SO_2R^9$, $-CO_2R^9$, $-C(=O)R^9$, alkyl having 1-8 carbons; alkenyl having 2 to 8 carbons, and alkynyl having 2 to 8 carbons, wherein

1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or

2) each alkyl, alkenyl, or alkynyl group is substituted with 1 to 3 groups selected from the group consisting of aryl having from 6 to 10 carbons, heteroaryl, arylalkoxy, heterocycloalkoxy, hydroxylalkoxy, alkyloxy-alkoxy, hydroxyalkylthio, alkoxy-alkylthio, F, Cl, Br, I, -CN, $-NO_2$, -OH, $-OR^9$, - $X^2(CH_2)_pNR^{11}R^{12}$, $-X^2(CH_2)_pC(=O)NR^{11}R^{12}$, $-X^2(CH_2)_pOC(=O)NR^{11}R^{12}$, $-X^2(CH_2)_pCO_2R^9$, $X^2(CH_2)_pS(O)_yR^9$, $-X^2(CH_2)_pNR^{10}C(=O)NR^{11}R^{12}$, $-OC(=O)R^9$, $-OCONHR^2$, -O-tetrahydropyranyl, $-NR^{11}R^{12}$, $-NR^{10}CO_2R^9$, $-NR^{10}C(=O)NR^{11}R^{12}$, $-NHC(=NH)NH_2$, $NR^{10}C(=O)R^9$, $-NR^{10}S(O)_2R^9$, $-S(O)_yR^9$, $-CO_2R^2$, $-C(=O)NR^{11}R^{12}$, $-C(=O)R^2$, $-CH_2OR^{10}$, $-CH=NNR^2R^{2A}$, $-CH=NOR^2$, $-CH=NR^9$, $-CH=NNHCH(N=NH)NH_2$, $-S(=O)_2NR^2R^{2A}$, $-P(=O)(OR^{10})_2$, $-OR^{14}$, and a monosaccharide having from 5 to 7 carbons wherein each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H, alkyl having from 1 to 4 carbons, alkylcarbonyloxy having from 2 to 5 carbons, or alkoxy having

from of 1 to 4 carbons;

R^{18} is selected from the group consisting of R^2, thioalkyl of 1-4 carbons, and halogen;

A^1 and A^2 are selected from the group consisting of H, H; H, OR^2; H, $-SR^2$; H, $-N(R^2)_2$; and a group wherein A^1 and A^2 together form a moiety selected from the group consisting of =O, =S, and $=NR^2$;

B^1 and B^2 are selected from the group consisting of H, H; H, $-OR^2$; H, $-SR^2$; H, $-N(R^2)_2$; and a group wherein B^1 and B^2 together form a moiety selected from the group consisting of =O, =S, and $=NR^2$; with the proviso that at least one of the pairs A^1 and A^2, or B^1 and B^2, form =O;

with the proviso that when Q is NH or NR^{7A}, and in any R^7 or R^{7A} group m is 0 and G is a bond, R^8 is H, and R^7 or R^{7A} contains one ring hetero oxygen atom at position A in a 5- or 6-membered ring, then B cannot be CHR^{17} where R^{17} is substituted or unsubstituted alkyl; and

with the further proviso that the compound of Formula I contains one R^7 or R^{7A} group or both an R^7 and R^{7A} group.

2. (Amended) The compound of claim 1 wherein:

A and B are independently selected from the group consisting of O, N, S, CHR^{17}, $C(OH)R^{17}$, C(=O), and CH2=C;

R^{17} is selected from the group consisting of H, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy; wherein:

1) ring J contains 0 to 3 ring heteroatoms;

2) any two adjacent hydroxyl groups of ring J can be joined in a dioxolane ring;

3) any two adjacent ring carbon atoms of ring J can be joined to form a fused aryl or heteroaryl ring;

provided that:

1) [ring J contain] <u>one of A, B, C, D, E, or F contains</u> at least one carbon atom that is saturated;

2) ring J <u>does</u> not contain two adjacent ring O atoms;

3) ring J contains a maximum of two ring C(=O) groups;

[4) when G is a bond, ring J can be heteroaryl;] and

R^8 is selected from the group consisting of O(C=O)$NR^{11}R^{12}$, -CN, acyloxy, alkenyl, -O-CH_2-O-$(CH_2)_2$-O-CH_3, halogen and R^{1A} wherein R^{1A} is the same as R^1.

8. (Amended) The compound of claim 2 wherein Q is NR^{13} or NR^{7A}.

9. (Amended) The compound of claim 8 wherein [preferably wherein R^{13} is H or R^{7A}] Q is NR^{7A}.

10. (Amended) The compound of claim [9] 8 wherein R^{13} is H.

16. (Amended) The compound of claim 15 wherein R^7 is a [3-, 4-, 5- or 6-membered] heterocyclic ring which contains one ring O atom.

35. (Amended) The compound of claim 31 wherein the constituent variables of the compounds of Formula II are selected in accordance with [Table 7] the following table:

A1A2	B1B2	R3	R5	R18	m	R8	A	B	C	D	E	F
H2	O	H	H	H	0	OH	CH2	CH2	N(Bn)	bond	CH2	CH2
H2	O	H	H	H	0	OH	CH2	CH2	O	bond	CH2	CH2
H2	O	H	H	H	1	H	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	C(=O)	CH2	CH2	CH2	bond
H2	O	H	H	H	0	H	O	C(=O)	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	(p)-F-phenyl	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	2-theinyl	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	OH	CH2	CH2	N(Me)	bond	CH2	CH2

H2	O	H	H	H	0	H	CH2	S	CH2	CH(OH)	bond	bond
H2	O	H	H	H	1	H	O	CH2	CH2	CH2	CH2	bond
H2	O	H	H	H	0	H	O	CH2	CH2	CH2	CH2	bond
H2	O	H	H	H	0	OH	CH2	CH2	S	bond	CH2	CH2
H2	O	H	H	H	0	OH	CH2	1,6-benzo-fused		bond	CH2	CH2
H2	O	H	H	H	0	OH	CH2	N(Et)	CH2	bond	CH2	CH2
H2	O	H	H	H	0	OH	CH[CH2-N{(CH2)2}2O]	CH2	bond	bond	CH2	CH2
H2	O	H	H	H	0	OH	CH2	CH2	CH2	bond	bond	bond
H2	O	H	H	H	3	Cl	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	O(C=O)-t-Bu	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	OH	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	O(C=O)CH3	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	CH(OH)	CH2	CH2	bond	bond
H2	O	H	H	H	0	OH	CH2	CH2	N[(C=O)CH3]	bond	CH2	CH2
H2	O	H	H	H	1	H	O	CH2	-C(=CH2)-	CH2	bond	bond
H2	O	H	H	H	1	H	O	CH2	-C[(OH)(CH2OH)]-	CH2	bond	bond
H2	O	H	H	H	1	H	O	CH2	-C(=O)-	CH2	bond	bond
H2	O	H	H	H	0	-CH=CH2	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	-CH(OH)CH2-OH	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	H	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	H	O	CH2	CH2	CH2	bond	bond

H2	O	H	H	H	1	-OCH2OCH2-O CH2OCH3		-C(=O)-	CH2	CH2	bond	bond
H2	O	H	H	Et	1	-O(C=O)CH2-O t-Bu		CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	OH	O	-C(=O)-	CH2	CH2	bond	bond
H2	O	H	H	Et	1	OH	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	OH	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	OH	O	CH2	CH2	CH2	bond	bond
O	H2	H	H	H	1	H	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	CH(OH)	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	CH(OEt)	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	CH(OEt)	CH2	CH2	bond	bond
H2	O	H	H	H	0	OH	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	CH2	CH2	CH(OH)	bond	bond
H2	O	H	H	H	1	Cl	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	O	1,6-[2,4-(OMe)2])-benzo-fused		CH2	bond	bond
H2	O	H	H	H	0	H	O	1,6-[2,4-(OMe)2])-benzofused		CH2	bond	bond
H2	O	H	H	Et	0	H	O	1,6-[2,4-(OMe)2])-benzofused		CH2	bond	bond
H2	O	H	H	H	0	OH	C(=O)	O	CH2	-C[(CH3)2]-	bond	bond
H2	O	H	H	H	0	OH	O	-CH[O(CMe2)O]CH-		CH2	bond	bond
H2	O	H	H	H	0	OH	CH2	CH2	CH2	CH2	CH2	bond
H2	O	H	H	H	1	H	O	CH(OEt)	CH2	O	CH2	bond
H2	O	H	H	H	1	H	O	CH(OEt)	CH2	O	CH2	bond
H2	O	H	H	H	1	H	O	CH(OEt)	CH2	O	CH2	bond

H2	O	3-C(=O)O-CH2CH2-OCH3	H	H	O	H	O	CH(OOCH2-CH2OCH3)	CH2	CH2	bond	bond
H2	O	H	10-O-Me	H	1	OH	O	CH2	CH2	CH2	bond	bond
H2	O	H	10-O-Me	H	1	OH	O	CH(OEt)	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	CH(COOEt)	C(=O)	CH2	CH2	bond	bond
O	O	H	H	H	0	H	CH(COOEt)	C(=O)	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	CH2	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	0	H	C(=O)	O	CH2	CH2	bond	bond
H2	O	H	H	H	1	OC(=O)NHEt	O	CH2	CH2	CH2	bond	bond
H2	O	H	H	H	1	OH	O	CH2	CH2	CH2	bond	bond.

---

50. (Amended) The compound of claim 49 wherein R^8 is [-O-(C=O)-CH_3] <u>-O-C(=O)-CH_3</u>.

52. (Amended) The compound of claim 51 wherein Q is NR^{7A} and W is [CHR^{17}] <u>$CR^{18}R^7$</u>.

53. (Amended) The compound of claim 52 wherein [wherein] R^{7A} and [R^{17}] <u>R^7</u> are each cyclopropylmethyl.

55. (Amended) The compound of claim 54 wherein [R^{7A} is] G is CH_2, m is 0, R^8 is -CN, and ring J is cyclopropyl.

65. (Amended) The pharmaceutical composition of claim [23] <u>64</u> wherein the prostate disorder is prostate cancer or benign prostate hyperplasia.

68. (Amended) A method for inhibiting a kinase comprising [comprising] providing a compound of claim 1 in an amount sufficient to result in effective inhibition.

73. (Twice Amended) A method for treating prostate disorders which comprises administering to a host in need of such treatment [or prevention] a therapeutically effective amount of a compound of claim 1.

91. (Amended) A method for the treatment of cancer comprising inhibiting one or more of Src, raf, a checkpoint kinase or a cyclin-dependent kinase, the method comprising providing a compound of claim 1 in an amount sufficient to result in the receptor being contacted with an effective inhibitory amount of the compound.

New claims 96 to 100 have been added.